Actively Recruiting
Phase 1 Study of Short Course Radiation Therapy for Adults with Primary or Recurrent Retroperitoneal Sarcoma Before Surgery
Led by Brigham and Women's Hospital · Updated on 2025-10-14
6
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety of a shorter course of radiation therapy, called moderately hypofractionated radiation, for treating primary and locally recurrent retroperitoneal sarcoma RPS. This phase I trial focuses on assessing the acute side effects related to radiation within 30 days after treatment. The study is sponsored by Brigham and Womens Hospital and aims to better understand the toxicity profile of this radiation approach. Participants receive hypofractionated radiation therapy, with a dose of 2.85 Gy given over 15 sessions totaling 42.75 Gy. If multiple patients experience dose-limiting toxicities, the radiation dose may be lowered to 2.7 Gy over 15 sessions 40.5 Gy. This treatment is delivered before surgery to the retroperitoneal tumor, and it involves a shorter radiation schedule than traditional therapies. During the study, participants will be closely monitored for side effects from radiation from enrollment until 30 days after completing treatment. Evaluations include imaging scans such as CT or MRI to confirm measurable disease, and assessments of kidney, bone marrow, liver function, and overall health status. Safety and toxicity data will guide dose adjustments, and participants will be followed until the end of the study period in November 2026.
CONDITIONS
Brief Title
Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery
Research Team
M
Miranda Lam
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here